Cancer

[NYBob]

MediPharm Labs Reports First Quarter Results
T.LABS | May 16, 2022
TORONTO, May 16, 2022 /PRNewswire/ -

MediPharm Labs Corp. (TSX: LABS)
(OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the
"Company") a pharmaceutical company specialized in precision-based
cannabinoids, today announced its financial results for the three months ended
March 31, 2022.

MediPharm Labs Logo (CNW Group/MediPharm Labs Corp.)

Q1 2022 – Select Operating Highlights
Continued leadership in global cannabis pharmaceuticals – poised to grow in U.S. market

In Q1, MediPharm entered the United States pharmaceutical market with the
completion of the FDA Drug Master File (the "DMF") process for pure natural CBD
APIs.
A first for CBD by a Canadian company and the second natural CBD DMF at
commercial scale in North America, the DMF allows for the registration of APIs
with the FDA for commercial opportunities in pharmaceutical development, novel
drugs, and generic drugs.
The cannabis-based drug opportunity is predicted to be over USD$25 billion by
20251.

https://stockhouse.com/news/press-releases/2022/05/16/medipharm-labs-reports-first-quarter-results

Contact Information
Address
151 John Street, Barrie, ON, CA, L4N 2L1
Telephone
[phone]
Website
https://www.medipharmlabs.com
Fax
[phone]
https://investorshub.advfn.com/MediPharm-Labs-Corp-36262

https://stockhouse.com/news/newswire/2022/03/11/the-stocktalk-cannabis-report-mar-11-2022